Yulia Dyachkova is a highly experienced biostatistician with over 25 years in the pharmaceutical industry across multiple therapeutic areas (neuroscience, cardiovascular, pulmonary, and most extensively oncology). Passionate about working with cross-functional teams and helping non-statisticians understand statistical concepts, she has made significant contributions in the medical affairs area. Yulia has led all aspects of statistical launch activities in a broad variety of global markets including responsibility in HTA, RWE, generating and interpreting real world evidence, designing phase IV studies. She has been involved as author/co-author of many manuscripts published in medical and statistical peer review journals.
Currently, Yulia works at Merck as an Associate Director Biostatistician. Yulia holds a Master degree in Biostatistics, from University of British Columbia, Vancouver.

Nathalie Barbier is an experienced leader of statisticians with more than 30 years’ experience in the pharmaceutical industry. She has a broad range of experience in successful drug development projects, from pre-clinical research to post submission profiling and health economics within different therapeutic areas. She is currently Global group Head in Global Medical Affairs and Access Biostatistics at Novartis Pharma Basel.

Cornelia Dunger-Baldauf has more than 30 years of experience in the pharmaceutical industry as a lead statistician in roles with increasing levels of responsibility. When overseeing all development phases of a Therapeutic Area, her responsibility included RWE evaluation. RWE became one of her research topics. She joined the Statistical Methodology Group at Novartis 3 years ago to lead a team working on a project which combines evidence from RCTs and clinical practice.